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Abstract
DC-SIGN (CD209) is a C-type lectin expressed by several groups of dendritic cells (DC), including
those derived from blood monocytes and DC found beneath genital epithelium. DC-SIGN binds the
envelope glycoprotein of HIV-1 and facilitates transmission of infectious virus to permissive CD4+ T
cells. We have compared the capacity of DC-SIGN in different cell types to bind, retain and transmit
infectious HIV-1 to T cells. The analyzed cells included monocyte-derived DC, and three different
DC-SIGN-expressing transfectants termed THP, 293 and HOS. Our results show that DC-SIGN
transfectants were able to bind HIV-1 virions comparably to DC. However, only the THP monocytic
cell line shared with DC the capacity to retain for several days virus that was infectious for T cells.
In both THP-DC-SIGN transfectants and DC, but not in 293 cells, HIV-1 was localized to intracellular
compartments that did not double label for endosomal and lysosomal markers or for DC-SIGN
itself. Virus remained detectable in these compartments for at least 2 days. Anti-DC-SIGN
antibodies blocked the binding and transmission of HIV-1 in DC-SIGN transfectants, as monitored
by PCR for HIV LTR/gag and p24 ELISA. However anti-DC-SIGN antibodies did not block virus
binding and transmission to T cells as well in DC as in THP-DC-SIGN transfectants. Thus, the
function of DC-SIGN in HIV-1 transmission depends on its cellular context, since only DC and the
THP monocyte cell line, but not 293 and HOS, are able to use DC-SIGN to retain HIV-1 in a highly
infectious state for several days.
Introduction
Dendritic cells (DC) are antigen-presenting cells found at
body surfaces and in lymphoid tissues (1). DC can migrate
from peripheral tissues and blood to lymphoid organs where
they interact with T cells. Therefore DC are critically positioned
to capture HIV-1 and spread the infection to CD4+ T cells. The
entry of HIV-1 into cells requires the interaction of viral
envelope protein, gp120, with two cell surface receptors.
CD4 binds HIV-1, while the chemokine receptors CCR5 and
CXCR4 serve as co-receptors for entry of R5 and X4 viruses
respectively (2). HIV-1 entry into target cells can be in¯uenced
by several additional factors. Heparin sulfate and mannose
receptors may facilitate attachment of virions to the cell
surface (3±5), and co-receptors may need to be clustered (6)
and/or be located in lipid rafts (7).
DC-SIGN (DC-Speci®c ICAM-3 Grabbing Non-integrin;
CD209) is a C-type lectin that speci®cally recognizes glycan
ligands (8). DC-SIGN is expressed primarily on DC, such as
those derived from blood monocytes as well as DC located
beneath genital surfaces and within lymphoid tissues (9). DC-
SIGN is already known to have several functions. It can
participate in the interactions between DC and T cells by
binding ICAM-3 (10). DC-SIGN also can bind ICAM-2 on
endothelial cells and potentially regulate the transmigration of
DC from blood into tissues (11). Non-viral pathogens like
Leishmania amastigotes (12) as well as other viral pathogens
like Ebola (13,14), SIV-1, SIV-2 (15), HIV-2 (15) and HCV (16)
can bind to DC-SIGN. Importantly, DC-SIGN binds the gp120
envelope glycoprotein of HIV-1 (15,17,18) and facilitates the
transmission of HIV-1 from DC-SIGN transfectants to target
CD4+ T cells (15,18,19). Originally it was shown that DC-SIGN
could function independently from CD4 and CCR5 to transmit
virus to permissive T cells (18,19). More recently it was also
noted that cis expression of DC-SIGN in transfectants permit-
ted more ef®cient entry of HIV-1 and SIV via CD4 and co-
receptor (20). DC-SIGN contains putative tyrosine and
dileucine motifs in its cytosolic domain (21), and can act as
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an endocytic receptor facilitating processing and presentation
of antigens (22). The endocytic function of DC-SIGN plays an
important role in its capacity to transmit HIV-1 to T cells (19).
Although it is known that DC-SIGN can enhance HIV-1
infection of T cells, it was of interest to explore the cellular
environment required for the capacity of DC-SIGN to retain
and transmit infectious HIV-1 over the course of several days.
Here we have compared the capacity of DC-SIGN in different
cellular contexts to bind and retain infectious virus for 2±6 days
in culture, and then transmit HIV-1 to T cells. Three different
types of transfectants were able to bind HIV-1, but only the
THP monocytic cell line shared with DC the capacity to
internalize and retain HIV-1 in an infectious state for presen-
tation to T cells. Our ®nding that DC-SIGN retains infectious
HIV-1 in select cell types may help to characterize the function
of this lectin in disseminating HIV-1 and other pathogens.
Methods
Plasmid preparation
Full-length DC-SIGN was PCR ampli®ed from a human thymic
cDNA library. The primers used for PCR ampli®cation were: 5-
hDC-SIGN (5¢-GACATGAGTGACTCCAAGGAACCAAGACT-
GCAGCA-3¢, with an EcoRI site), 3-hDC-SIGN (5¢-CTAC-
GCAGGAGGGGGGTTTGGGGTGGCAG-3¢, with BamHI and
NotI sites). The sequence of full-length DC-SIGN was con-
®rmed to be identical with the published sequences from
Curtis et al. (17) and Geijtenbeek et al. (18). DC-SIGN was
cloned into the mammalian expression vector pN1-eGFP
(Clontech, Palo Alto, CA) to which green ¯uorescence protein
has been deleted, but which still retains the neomycin (G418)
selection marker.
DC
To prepare DC from precursors in blood, CD14+ monocytes
were positively selected from peripheral blood mononuclear
cells (PBMC; from buffy coat or venapuncture specimens)
using CD14 magnetic beads as suggested by the vendor
(Miltenyi Biotec, Auburn, CA). CD14+ cells (1.5 3 106) were
plated in six-well dishes in 3 ml RPMI 1640 medium supple-
mented with 5% human serum, recombinant granulocyte
macrophage colony stimulating factor (100 IU/ml, Leukine;
Immunex, Seattle, WA) and recombinant human IL-4 (20 ng/
ml; R & D Systems, Minneapolis, MN). The cells were fed on
days 2 and 4 with the same concentration of the cytokines. At
day 6, most of the non-adherent cells were immature DC with a
CD14±, HLA-DR+, CD3± and CD83± phenotype. Mature CD83+
DC then were induced by adding in¯ammatory cytokines (IL1-
b, tumor necrosis factor-a and IL-6 at 10 ng/ml, and
prostaglandin E2 at 1 mg/ml).
Transfectants
293 (human embryonic kidney) and HOS (human osteosarco-
ma) cells, obtained from the AIDS Research and Reference
Reagent Program, expressing DC-SIGN were generated by
stable transfection using the Lipofectamine agent, as sug-
gested by the vendor (Gibco/BRL, Gaithersburg, MD).
Geneticin-resistant clones were expanded and analyzed by
¯ow cytometry using anti-DC-SIGN antibodies. Similarly, HOS
cells expressing CD4 and CCR5 (obtained from the AIDS
Research and Reference Reagent Program) were transfected
with DC-SIGN plasmid. HOS cells were maintained in DMEM
medium (Gibco/BRL) supplemented with 10% FCS, 1 mg/ml
puromycin and 1 mg/ml geneticin. THP, a monocytic cell line,
and THP-DC-SIGN transfectants were kindly provided by Dr
Dan Littman (New York University). MAGI, a HeLa cell clone
expressing human CD4, CCR5 and HIV-LTR-b-gal developed
by Michael Emerman's laboratory, was obtained from the NIH
AIDS Research Reagent Program.
Quantitation of HIV-1 receptors
Primary DC and DC-SIGN transfectants were stained with
the anti-DC-SIGN mAb 507 and 612 (R & D Systems), anti-
CD4±phycoerythrin (PE) (clone Leu-3a; Becton Dickinson,
San Jose, CA), and anti-CCR5 (clone 2D7; PharMingen,
San Diego, CA). Cells were incubated for 45 min at 4°C with
each antibody diluted to the optimal concentration for
immunostaining. After washing with cold PBS supplemented
with 2% FCS, the cells were incubated with PE-conjugated
mAb (Biosource, Camarillo, CA) for 30 min at 4°C, washed a
further 3 times and analyzed on a FACScan with CellQuest
software (Becton Dickinson). To quantify expression of HIV-1
receptors, we used a quantitative FACS assay (QFACS) with
microbeads containing known amounts of anti-Ig molecules
(Sigma, St Louis, MO).
HIV-1 infection of cells
Cells were infected with the Ba-L isolate, grown in mitogen-
stimulated PBMC and tittered in MAGI cells to determine
infectious units (IU). In general, 105 cells were pulsed with
graded doses of HIV-1 Ba-L starting with 300 pg, equivalent to
3000 IU or 0.03 m.o.i. for 2 h at 37°C. In the experiments in
which the effect of antibodies were studied, the indicated
antibodies were added for 30 min at room temperature before
virus addition and kept during the infection period. The cells
were washed 4 times and 5 3 104 virus-pulsed cells co-
cultured with phytohemagglutinin-activated PBMC (1 3 105)
immediately after the 2-h HIV-1 pulse or after 2±6 days of
culture. To avoid overgrowth, the HIV-1-pulsed transfected
cells were exposed to ionizing irradiation (1500 rad). Culture
supernatants were collected at different time points and the
p24 antigen released into supernatants measured by ELISA.
For PCR analysis, infected cultures were collected at the
indicated time points and proviral DNA was ampli®ed for the
detection of early (RU/5) and late reverse transcripts (LTR/
gag) as previously described (23). HIV-1 copy numbers in
50,000 cells per lane were estimated by comparison with
graded doses of ACH-2 cells, which contain one copy of
proviral DNA per cell. HLA-DQ sequences were ampli®ed as a
control for DNA input. For detection of p24 at the single-cell
level, infected cultures were ®xed with 4% paraformaldehyde
in PBS for 30 min on ice. Cells were permeabilized for 15 min in
0.1% saponin, and double stained with p24±FITC (Coulter,
Miami, FL) and CD3±PE (clone SK7; BD PharMingen, San
Diego, CA).
HIV-1 binding assays
To analyze the binding of HIV-1 Ba-L to cells, the cells were
preincubated with or without antibodies for 20 min at room
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temperature before the addition of HIV-1 (300 pg). Cells were
extensively washed after 2 h; part of the cells were then lysed
in 0.5 % Triton, and the rest were cultured for 2 days and then
lysed. Cell lysates were assayed for p24 by ELISA (Coulter).
Confocal microscopy
DC-SIGN-expressing cells were infected on ice or at 37°C with
Aldritiol-2 (AT-2) (24)-inactivated HIV-1 particles at a high
dose, 100 ng/105 cells (a kind gift of J. Lifson), and washed.
The cells were examined after 2 h and 2 days of culture. For
microscopy, the cells were attached to printed slides (Carlson
Scienti®c, Peotone, IL) coated with polylysine (Sigma) and left
to adhere at 37 or 4°C for 30 min in serum-free medium. The
cells were washed and ®xed for 30 min in 4% paraformalde-
hyde in PBS. Fixed cells were permeabilized in 0.05% saponin
for 15 min, and double stained for HIV-1 gag (mAb KC57
FITC±IgG1; Coulter) and anti-DC-SIGN (clone 507; IgG2b) for
1 h at room temperature followed by goat anti-IgG2b Alexa
546 at a dilution of 1:300 (Molecular Probes, Eugene, OR). We
also stained cells with combinations of anti-gag and anti-
caveolin (Santa Cruz Biotechnology, Santa Cruz, CA), anti-
EEA1 (Santa Cruz Biotechnology), and anti-LAMP±biotin
(PharMingen). Nuclei were stained with DAPI. Fluorescence
was examined with a model AX70 Olympus laser scanning
microscope.
Results
Quantitation of DC-SIGN expression on DC and
transfectants
To further understand the involvement of DC-SIGN in HIV-1
infection, we established several cell lines stably expressing
DC-SIGN. Quantitation of DC-SIGN and other receptors for
HIV-1 (CD4, CCR5) on each cell type was assessed using Ig-
coated ¯uorescent beads. As expected from prior reports,
immature DC expressed the two co-receptors for HIV-1, CD4
and CCR5, and high levels of DC-SIGN (Fig. 1). In contrast, the
293 and THP cell lines were negative for all three HIV-1-
binding molecules (Fig. 1). Upon transfection with DC-SIGN,
the cell lines expressed the protein. The expression of DC-
SIGN on the transfectants was stable over the course of
multiple experiments and the different cell lines expressed
comparable average levels of DC-SIGN per cell (Fig. 1).
Interaction of HIV-1 with DC-SIGN-expressing cells
To measure the binding of HIV-1 to DC-SIGN-expressing cells,
cells were incubated with relatively low doses of virus (3000 IU
corresponding to 300 pg of p24/105 cells) for 2 h, washed and
lysed in 0.5% Triton. Cell lysates were assessed for virus
binding by quantifying HIV-1 gag (p24) by ELISA. The added
virions bound to cells expressing DC-SIGN ef®ciently (Fig. 2;
4±10 pg of bound p24) and the extent of binding depended on
the input dose of virus (not shown). Background binding to
cells expressing vector alone was low (Fig. 2). Two different
commercially available DC-SIGN antibodies (507 reacting with
DC-SIGN and 612 reacting with DC-SIGN/DC-SIGNR) and the
AZND1 antibody (18) were used to inhibit HIV-1 binding. The
inhibition was at least 50% on 293-DC-SIGN cells and >95%
on THP-DC-SIGN transfectants (Fig. 2A). Therefore, the
transfectants used DC-SIGN to bind HIV-1 and, in the case
of THP cells, mAb to DC-SIGN almost totally blocked binding.
Next, binding of HIV-1 was assessed in immature DC and
DC matured with in¯ammatory cytokines. Both types of DC
express the receptors for HIV-1, CD4, CCR5 and DC-SIGN,
with higher expression of the receptors on the immature cells
(not shown). The level of CD4 and CCR5 expression varied in
immature DC from different donors at least 10-fold, but there
was much less variation with respect to DC-SIGN. HIV-1
bound to DC comparably to DC-SIGN transfectants analyzed
in parallel, but the anti-DC-SIGN antibodies only slightly
decreased HIV-1 binding to DC; in contrast the THP-DC-
SIGN transfectants that were almost totally blocked (cf. Fig. 2A
with B). T blasts, which were negative for DC-SIGN
Fig. 1. Expression of HIV-1 receptors on DC and DC-SIGN
transfectants. The number on each panel represents antibody-
binding sites quanti®ed as described in Methods. The histograms
re¯ect binding of the speci®c antibody (gray) and isotype-matched
control antibody (white).
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expression, were at least 4- to 5-fold less active in binding HIV-
1 than DC-SIGN transfectants or DC and the binding to T
blasts was not sensitive to anti-DC-SIGN antibodies (not
shown).
We then assessed retention of the captured virus in
culture for 2 days after infection. The amount of virus
retained by DC and THP-DC-SIGN cells at this time point
was 10 times less compared to the 2-h pulse (Fig. 2C).
Nevertheless, we could readily quantify virus by p24 ELISA
(Fig. 2C). It is worth noting that although the level of p24
retained by the cells after 2 days was reduced, the
retained virus, as seen below, was still suf®cient to set up
a robust infection in T cells.
Thus, cells differ in their capacity to retain HIV-1 and also DC
differ from DC-SIGN transfectants in that anti-DC-SIGN anti-
bodies do not ef®ciently block HIV-1 binding.
Fig. 2. Binding of HIV-1 to DC and DC-SIGN transfectants. Cells (105) were incubated with anti-DC-SIGN antibodies or isotype controls at a
concentration of 15 mg/ml for 20 min at room temperature and then infected with HIV-1 (300 pg of p24 that is equivalent to 3000 IU) for 2 h at
37°C. Some cells were washed and lysed in 0.5% Triton X-100 immediately, while others were lysed after 2 days. The amount of p24 antigen
in the cell lysates was quanti®ed by ELISA. Each symbol corresponds to an individual experiment. (A) HIV-1 captured by DC-SIGN
transfectants after 2 h. (B) HIV-1 captured by immature and mature DC after 2 h. (C) Comparison of HIV-1 bound to cells after a 2-h capture
(day 0) and retained by cells after 2 days (day 2).
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Effect of anti-CD4, RANTES and anti-DC-SIGN antibodies
on direct infection of DC, T blasts and DC-SIGN
transfectants
We monitored infection and entry in cells at the level of early
reverse transcripts of proviral DNA. The anti-CD4 antibodies
and RANTES blocked the infection in DC and T blasts,
whereas anti-DC-SIGN antibodies did not (Fig. 3). However,
as expected from their lack of CD4 and CCR5 (Fig. 1), THP-
DC-SIGN cells were not susceptible to infection. To assess the
role of DC-SIGN in transfectants that express CD4 and CCR5,
we made stable DC-SIGN transfectants in HOS cells previ-
ously transfected with CD4 and CCR5. As seen in Fig. 1, DC-
SIGN is highly expressed in these transfectants. Virus entry
was blocked by anti-CD4 antibodies and RANTES, but not by
anti-DC-SIGN antibodies, in HOS-CD4-CCR5 or HOS-CD4-
CCR5-DC-SIGN transfectants (Fig. 3). Thus, CD4 and CCR5,
but not DC-SIGN, serve as receptors for virus entry into both
HOS cells and DC. We next investigated transmission of HIV-1
from DC-SIGN-expressing cells to activated T cells, since this
may proceed independently of infection.
DC-SIGN-expressing cell lines differ in their capacity to
retain infectious HIV-1 for transmission to T cells
We compared the DC-SIGN transfectants to DC for their
capacity to retain infectious HIV-1, using cells that were
exposed to virus for 2 h at 37°C, washed and then added to T
cells immediately or after 3±6 days in culture. The latter
approach was to test whether the virus retained by the DC-
SIGN-expressing cells was infectious for subsequent trans-
mission to T cells. As seen in Fig. 4A (left panel), if activated T
cells were added immediately after infection, both 293-DC-
SIGN and THP-DC-SIGN cells could transmit HIV-1, much like
DC. However, 293-DC-SIGN cells were unable to retain the
virus in an infectious state for 3 days (Fig. 4A, middle panel).
The lack of T cell infection was also evident even when
activated T cells were added 24 h after infection of 293-DC-
SIGN cells (not shown). HOS-DC-SIGN cells acted similarly to
the 293 transfectants, being able to transfer virus to T cells
only if tested immediately and not if cultured 1±3 days prior to
addition of the T cells (Fig. 4B). In contrast, infected THP-DC-
SIGN cells and DC could still transmit virus to activated T cells,
even when the T cells were added 3 days later (Fig. 4A, middle
panel). If T blasts were added after 6 days, only DC but not
THP-DC-SIGN cells could transmit HIV-1 (Fig. 4A, right panel).
Therefore, the DC and THP-DC-SIGN transfectants, but not
293 or HOS transfectants, could retain HIV-1 in a form that is
infectious for T cells for at least 3 days, whereas DC could
transmit infection to T cells even after 6 days.
Effect of anti-DC-SIGN antibodies on transmission of HIV-1
from DC-SIGN transfectants and DC to T cells
Several anti-DC-SIGN antibodies were also tested for their
capacity to block HIV-1 transmission from HIV-1-infected cells
to T cells. Two different assays were utilized with cells that
were preincubated with anti-DC-SIGN antibodies, exposed to
virus for 2 h and after extensive washes co-cultured with
activated T cells. First, to detect early infection in T cells, LTR/
gag sequences were analyzed by PCR after 36 h of co-culture.
Anti-DC-SIGN antibodies completely inhibited virus transfer
from THP-DC-SIGN cells as visualized by PCR (Fig. 5A),
con®rming previous results (14,19). In contrast, DC-SIGN
antibodies did not completely block the transfer of HIV-1 from
either immature or mature DC (not shown) to T cells (Fig. 5A),
even when the two antibodies were used at 20 mg/ml. As seen
in Fig. 5(A), the AZND1 antibody inhibited more strongly than
the 612 and 507 antibodies (or the combination of 507 and
612; data not shown). Second, HIV-1 transfer over longer
culture periods was assessed by measuring p24 in the
supernatants by ELISA. With this assay we compared DC-
SIGN infected cells that were co-cultured with activated T cells
added at day 0 or after 2 days of infection (Fig. 5B). The results
were identical, indicating that in THP-DC-SIGN transfectants,
HIV-1 transmission is completely blocked by anti-DC-SIGN
antibodies (Fig. 5A and B, lower panels). In DC, anti-DC-SIGN
antibodies did not block HIV-1 transfer completely, but in
some experiments with higher doses of AZND1 antibody the
inhibition was 80±90% (Fig. 5B, upper panels). Thus, as noted
in the capture assay, in DC there may be an alternative DC-
SIGN-independent pathway whereby DC can bind and retain
HIV-1 for transmission to T cells.
Co-expression of DC-SIGN with CD4 and CCR5 enhances
viral infection and transmission in HOS cells
Previous work has shown that DC-SIGN either does not
mediate virus entry (18) or that cis expression of DC-SIGN
allows for more ef®cient entry of HIV-1 (20). The HOS
transfectants provided an opportunity to evaluate the role of
DC-SIGN in cells that also expressed the CD4 and CCR5
receptors for viral entry, like DC. For this, cells were infected
with different virus titers and then proviral DNA was ampli®ed.
We did observe a 3- to 5-fold increase in infection of the CD4-
and CCR5-expressing HOS cells when DC-SIGN was also
expressed, but only when the cells were infected with limiting
doses of HIV-1 (Fig. 6A). More impressive differences in
quantitative terms were seen during culture with T cells. When
the HOS-CD4-CCR5 cells were tested for HIV-1 transmission
to T cells (immediately after infection), the expression of DC-
SIGN markedly enhanced the production of p24 in the HOS-T
Fig. 3. Effect of HIV-1 receptor inhibitors on proviral DNA synthesis
in DC and DC-SIGN transfectants. The indicated cells were
pretreated or not for 20 min with anti-DC-SIGN antibodies 507 and
612 at 7.5 mg/ml each, anti-CD4 Leu3a and RPTA4 (PharMingen) at
7.5 mg/ml each or SDF1 and RANTES (R & D Systems) at 100 nM.
The cells were infected with 3000 IU of HIV-1. After 5 h, cells were
collected, washed and the equivalent of 5 3 104 assessed for RU/5
sequences by PCR indicative of early reverse transcripts. DQ
sequences were ampli®ed as a control for DNA input (23).
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cell co-culture. This was evident with a quantitative single-cell
staining of p24 in the T blasts by FACS (Fig. 6B). For the latter,
HOS transfectants were infected with HIV-1 and co-cultured
with activated T blasts for 6 days. CD3+ cells were gated and
enumerated for staining to newly produced intracellular p24
antigen. Infection of the T blasts was increased at least 10-fold
Fig. 4. Transmission of HIV-1 to T blasts by immature DC and DC-SIGN transfectants. Cells (105) were infected with 300 pg of p24 (equivalent
to 3000 IU) for 2 h at 37°C. Cells were washed and 5 3 104 infected cells were incubated immediately with 105 T blasts (day 0). In parallel,
other aliquots of virus-pulsed cells were cultured for 3 or 6 days prior to addition of T blasts (day 3 or day 6). p24 was measured in the
supernatants by ELISA at the indicated time points. (A) Comparison of DC with 293-DC-SIGN and THP-DC-SIGN transfectants. (B)
Comparison of DC with HOS-DC-SIGN.
294 DC-SIGN interaction with HIV-1 on dendritic cells and transfectants
 at Y
O
N
SEI U
N
IV
ERSITY
 M
ED
ICA
L LIBRA
RY
 on July 21, 2014
http://intim
m
.oxfordjournals.org/
D
ow
nloaded from
 
by the presence of DC-SIGN in the HOS cells transfectants.
Therefore, DC-SIGN is able, in CD4- and CCR5-bearing HOS
cells, to enhance infection and transmission to T blasts at low
virus titers.
Fig. 5. Effect of anti-DC-SIGN antibodies on HIV-1 transmission. Cells were incubated with the indicated doses of anti-DC-SIGN antibodies or
isotype controls at a concentration of 10 mg/ml for 20 min at room temperature and then infected with HIV-1 for 2 h at 37°C. Cells were washed
4 times and 5 3 104 infected cells co-cultured with 105 T blasts. (A) Detection of full-length proviral DNA (LTR/gag) after 36 h of co-culture. DQ
sequences were ampli®ed for control of DNA input (23). (B) p24 secreted in the culture media as detected by ELISA. Each symbol in the
middle and right panel corresponds to an individual experiment.
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Visualization of p24-containing compartments in HIV-1-
infected cells
To investigate the fate of bound and internalized virus in DC
and THP-DC-SIGN transfectants as a function of time, cells
were infected with high titers of AT-2-inactivated HIV-1 (24) for
2 h on ice or at 37°C and then washed to remove unbound
virus. The infected cells were attached to slides, and double
stained for p24 and speci®c markers of cellular compartments
immediately after the 2-h pulse with HIV-1 or after culture for 2
days. If cells were infected on ice, virus localized predomin-
antly at the surface, with some co-localization of p24 with DC-
SIGN (yellow labeling) in the transfected cells, consistent with
a function of DC-SIGN in virus capture in the transfectants
(Fig. 7). However, in DC, there was little overlap between the
DC-SIGN and anti-p24 labeling, suggesting alternative meth-
ods of virus binding than DC-SIGN (Fig. 7). When cells were
infected at 37°C for 2 h, p24 staining was detected within
intracellular granules, but there was no double labeling with
antibodies for several endocytic compartments. The intra-
cellular p24+ granules lacked EEA1 for early endosomes,
caveolin for caveolae or LAMP for late endosomes and
lysosomes (not shown); furthermore, there was no double
labeling for DC-SIGN and p24 (Fig. 7). When the infected cells
were studied after 2 days in culture, p24 persisted within
granules, often in the perinuclear region (Fig. 7), but again
without evident co-localization with DC-SIGN. However, virus
persistence was only observed in DC and THP-DC-SIGN cells,
and not in 293-DC-SIGN (Fig. 7). This indicates that in DC and
THP-transfectants, HIV-1 can be sequestered and retained in
vacuoles that are distinct from many known endocytic com-
partments, and that the virus may have dissociated from DC-
SIGN.
Discussion
The most interesting feature of these studies is that retention
and transmission of HIV-1 by DC-SIGN depend on the cellular
environment. Although 293-DC-SIGN and HOS-DC-SIGN bind
virus and transmit infectivity to activated T cells, this was
achieved only if T cells were added immediately after the virus
pulse. THP-DC-SIGN kept the virus in an infectious state for 2±
3 days, whereas only DC transmitted infectious virus after 6
days. This indicates that monocyte-derived cells retain virions
and competence to infect target T cells after a prolonged
period from primary infection. Some cell-restricted mechan-
isms, present in THP-1 and DC, but not in 293 and HOS, seem
to be required for DC-SIGN to exhibit its striking capacity to
retain HIV-1 in an infectious state for T cells. It has been shown
by others that following interaction of HIV with DC-SIGN, the
virus is rapidly internalized in THP-DC-SIGN (19). DC, like
THP-DC-SIGN cells, internalize HIV-1 and, by confocal
microscopy, virus could be visualized inside cells 2 days
after infection. However, the viral particles could not be
detected by microscopy in 293-DC-SIGN and HOS-DC-SIGN
after 2 days of infection. The intracellular p24+ compartments
did not double label with antibodies to early endosomes,
caveolae or late endosomes/lysosomes. At the time points
studied, the internalized virions also were not co-localized with
DC-SIGN, suggesting dissociation or weak interaction with
DC-SIGN. Thus, DC and the THP line have specialized
compartments that can protect viruses from degradation.
The function of these compartments in transmission of HIV-1 to
T cells may be critical, especially in the case of cells that have
similarity to the THP cells and DC used in this study.
A high amount of DC-SIGN is expressed by DC [Fig. 1
and (14,18)]. We speculate that, in addition to the seques-
tration and transmission of infectious HIV-1, an additional
function of DC-SIGN is to concentrate and tether low
amounts of virus to the cell surface, thus facilitating the
interaction with CD4 and CCR5. Alternatively virions bound
to DC-SIGN could undergo conformational changes that
increase binding af®nity for CD4 and CCR5. These situ-
ations may occur and recapitulate an in vivo infection. Our
hypotheses are supported by the results showing that CD4+
and CCR5+ cells transfected with DC-SIGN are infected
more ef®ciently at very low virus titers.
Transmission to T cells was greatly enhanced using DC-
SIGN transfected versus non-transfected cell lines and trans-
mission in the former was blocked often almost completely by
inclusion of anti-DC-SIGN antibodies. However, in the mono-
cyte-derived DC that we studied, the antibodies did not
completely block transmission. This was evident with three
different sources of anti-DC-SIGN antibodies that recognize
the carbohydrate recognition domain (CDR) of DC-SIGN
(9,18), although inhibition was more pronounced with the
AZND1 antibody. In DC, virus transmission seems to depend
on several factors such as direct infection with HIV-1 (25±28),
capture of virus by DC-SIGN (18,19) or by other transmitting
receptors homologous to DC-SIGN. Macaque DC express
very low levels of DC-SIGN, but are still able to transmit virus to
T cells (29), and in a recent study it was suggested that factors
other than DC-SIGN play a role in the ability of DC to transmit
HIV-1 (14). Interestingly enough, other DC subsets such as
Fig. 6. Expression of DC-SIGN on CD4 and CCR5 HOS
transfectants increases infection and transmission to T blasts. HOS
cells (105) were infected with the indicated viral doses of HIV-1 for 2
h at 37°C. After extensive washes, cells were studied directly (A) or
incubated with activated T cells (B). (A) Formation of LTR/gag
reverse transcripts after 1, 3 or 5 days of culture in HOS cells that
express CD4 and CCR5 in the absence or presence of DC-SIGN, at
two different doses of HIV-1. Graded doses of ACH-2 cell lysates
were ampli®ed in parallel for quantitation of proviral DNA in samples.
(B) FACS for p24 expression. HOS cells were infected with HIV-1
and, after washing, cells were co-cultured with activated T cells.
After 6 days, cells were collected, double stained for p24 and CD3,
and the gated CD3 cells were analyzed for p24.
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Langerhans cells and plasmacytoid cells express HIV-1 co-
receptors, and little or no DC-SIGN, but can be infected and
transmit HIV-1 (30,31). In contrast, a subset of DC-SIGN+ DC
in human blood was shown to transmit HIV-1 to T cells (32).
Others have shown that the role of DC-SIGN in the capture
of infectious agents extends beyond HIV-1 to other pathogens
like Leishmania (12), SIV (15), Ebola (13) and HCV (16). It will
be of interest to determine if the function of DC-SIGN in
supporting infection with these other agents also in some way
depends upon the presence of this C-type lectin in a DC
environment.
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